Showing Results for
- Academic Journals (12)
Search Results
- 12
Academic Journals
- 12
-
From:Future Oncology (Vol. 11, Issue 5) Peer-ReviewedAuthor(s): Richard J Epstein [*] aff1 aff2 aff3 KEYWORDS apoptosis; genetic instability; personalized medicine; tumor suppressor genes Scientific progress depends on the discovery of homologies and continuities...
-
From:Future Oncology (Vol. 11, Issue 5) Peer-ReviewedAuthor(s): Pingping Hu aff1 , Guanghui Wang aff2 , Meixiao Shen aff1 , Ping Zhang aff1 , Jihong Zhang aff1 , Jiajun Du [*] aff1 aff2 , Qi Liu [*] aff1 KEYWORDS epithelial-mesenchymal transition; esophageal cancer;...
-
From:Future Oncology (Vol. 11, Issue 5) Peer-ReviewedAuthor(s): Herbert H Loong aff1 aff2 , Kevin Mok aff3 , Linda KS Leung aff1 aff2 , Tony SK Mok [*] aff1 aff2 KEYWORDS acquired resistance; brain metastases; c-Met; crizotinib; EML4-ALK fusion; non-small-cell lung...
-
From:Future Oncology (Vol. 11, Issue 5) Peer-ReviewedAuthor(s): Camille C Gunderson aff1 , Kathleen N Moore [*] aff1 KEYWORDS BRCA mutation; homologous recombination pathway; PARP inhibitor; olaparib; ovarian cancer Approximately 22,000 cases of ovarian cancer...
-
From:Future Oncology (Vol. 11, Issue 5) Peer-ReviewedAuthor(s): Lev M Berstein [*] aff1 , Dmitry A Vasilyev aff1 , Aglaya G Iyevleva aff2 , Marina P Boyarkina aff1 , Tatyana E Poroshina aff1 , Angela S Khadzhimba aff3 , Evgeny N Imyanitov aff2 KEYWORDS cancer;...
-
From:Future Oncology (Vol. 11, Issue 5) Peer-ReviewedAuthor(s): Anna M Czarnecka [*] aff1 , Anna Kornakiewicz aff1 aff2 , Fei Lian aff3 , Cezary Szczylik aff1 KEYWORDS afinitor; combination treatment; everolimus; mTOR; RAD001; RECORD; renal cell cancer mTOR is a...
-
From:Future Oncology (Vol. 11, Issue 5) Peer-ReviewedAuthor(s): Felicity A Wright aff1 aff2 aff3 , Mary Bebawy aff3 , Tracey A O'Brien [*] aff1 aff4 KEYWORDS pediatrics; pharmacogenetics; polymorphism; stem cell transplantation; transplantation conditioning The...
-
From:Future Oncology (Vol. 11, Issue 5) Peer-ReviewedAuthor(s): Cecilia Arana Yi aff1 , Constantine S Tam aff2 , Srdan Verstovsek [*] aff3 KEYWORDS JAK inhibitor; myelofibrosis; myeloproliferative neoplasm; polycythemia vera; primary myelofibrosis; ruxolitinib;...
-
From:Future Oncology (Vol. 11, Issue 5) Peer-ReviewedAuthor(s): Shanthi Kanthala aff1 , Sandeep Pallerla aff1 , Seetharama Jois [*] aff1 KEYWORDS acquired resistance; afatinib; cetuximab; EGF receptor; gefitinib; neratinib; predictive markers; trastuzumab; tyrosine...
-
From:Future Oncology (Vol. 11, Issue 5) Peer-ReviewedAuthor(s): H Bindu Musunuru aff1 aff2 , Andrew Loblaw [*] aff1 aff2 aff3 KEYWORDS image-guided radiotherapy; prostate cancer; quality of life; stereotactic ablative radiotherapy Emerging evidence about the...
-
From:Future Oncology (Vol. 11, Issue 5) Peer-ReviewedAuthor(s): Konstantinos Liapis [*] aff1 , Jamie D Cavenagh aff2 KEYWORDS acute myeloid leukemia; azacitidine; older patients The median age at presentation for patients with acute myeloid leukemia (AML) is 67...
-
From:Future Oncology (Vol. 11, Issue 5) Peer-ReviewedAuthor(s): Kate Young aff1 , Ridhima Iyer aff1 , Daniel Morganstein aff1 , Ian Chau aff1 , David Cunningham aff1 , Naureen Starling [*] aff1 KEYWORDS DOTATATE; everolimus; NETs; neuroendocrine tumors; pancreatic...